Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFB002 vs sham injection in macular edema secondary to central retinal vein occlusion
CTR20131203Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in macular edema, sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on CTR20131203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131203.